Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

BACKGROUND: Long-term prophylaxis with subcutaneous C1-inhibitor (C1-INH[SC]; HAEGARDA, CSL Behring) in patients with hereditary angioedema (HAE) due to C1-INH deficiency (C1-INH-HAE) was evaluated in an open-label extension follow-up study to the international, double-blind, placebo-controlled COMP...

Descripción completa

Detalles Bibliográficos
Autores principales: Lumry, William R., Zuraw, Bruce, Cicardi, Marco, Craig, Timothy, Anderson, John, Banerji, Aleena, Bernstein, Jonathan A., Caballero, Teresa, Farkas, Henriette, Gower, Richard G., Keith, Paul K., Levy, Donald S., Li, H. Henry, Magerl, Markus, Manning, Michael, Riedl, Marc A., Lawo, John-Philip, Prusty, Subhransu, Machnig, Thomas, Longhurst, Hilary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885603/
https://www.ncbi.nlm.nih.gov/pubmed/33588897
http://dx.doi.org/10.1186/s13023-020-01658-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885603/
https://www.ncbi.nlm.nih.gov/pubmed/33588897
http://dx.doi.org/10.1186/s13023-020-01658-4

Ejemplares similares